Eric Crombez Biography and Net Worth

Director of Abeona Therapeutics

Dr. Crombez joined Ultragenyx following the acquisition of Dimension Therapeutics in November 2017. As Chief Medical Officer of Ultragenyx, Dr. Crombez is responsible for strategic leadership of the clinical development and translational research programs, and oversees global development functions including Clinical Development, Clinical Operations, BioMetrics, Endpoint Development and Strategy, Regulatory Affairs and Drug Safety/Pharmacovigilance. At Dimension Therapeutics, Dr. Crombez served as Chief Medical Officer and led the clinical development efforts for their gene therapy programs. Dr. Crombez is also an appointed industry representative on the FDA Cellular, Tissue and Gene Therapies Advisory Committee. Before joining industry, he was assistant professor, Department of Pediatrics, Division of Medical Genetics at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA). Dr. Crombez is a board-certified clinical geneticist and completed residencies in pediatrics and medical genetics and a fellowship in clinical biochemical genetics at the UCLA School of Medicine. Dr. Crombez obtained his B.S. degree in biology from the University of Michigan, Ann Arbor, and his M.D. degree from Wayne State University School of Medicine, Detroit.

What is Eric Crombez's net worth?: The estimated net worth of Eric Crombez is at least $453.99 thousand as of March 2nd, 2026. Crombez owns 76,301 shares of Abeona Therapeutics stock worth more than $453,991 as of May 4th. This net worth evaluation does not reflect any other investments that Crombez may own. Learn More about Eric Crombez's net worth.
How do I contact Eric Crombez?: The corporate mailing address for Crombez and other Abeona Therapeutics executives is 3333 LEE PARKWAY SUITE 600, DALLAS TX, 75219. Abeona Therapeutics can also be reached via phone at 214-665-9495 and via email at [email protected]. Learn More on Eric Crombez's contact information.
Has Eric Crombez been buying or selling shares of Abeona Therapeutics?: Eric Crombez has not been actively trading shares of Abeona Therapeutics over the course of the past ninety days. Most recently, Eric Crombez sold 16,284 shares of the business's stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $5.09, for a transaction totalling $82,885.56. Following the completion of the sale, the director now directly owns 63,456 shares of the company's stock, valued at $322,991.04. Learn More on Eric Crombez's trading history.
Who are Abeona Therapeutics' active insiders?: Abeona Therapeutics' insider roster includes Leila Alland (Director), Mark Alvino (Director), Michael Amoroso (CEO), Edward Carr (CAO), Faith Charles (Director), Eric Crombez (Director), Brendan O'Malley (SVP), Vishwas Seshadri (CEO), Christine Silverstein (Director), Madhav Vasanthavada (Insider), Joseph Vazzano (CFO), and Todd Wider (Director). Learn More on Abeona Therapeutics' active insiders.
Are insiders buying or selling shares of Abeona Therapeutics?: During the last twelve months, insiders at the biopharmaceutical company sold shares 29 times. They sold a total of 527,843 shares worth more than $2,987,597.61. The most recent insider tranaction occured on February, 2nd when Director Leila Alland sold 18,065 shares worth more than $91,950.85. Insiders at Abeona Therapeutics own 5.4% of the company. Learn More about insider trades at Abeona Therapeutics.
Information on this page was last updated on 2/2/2026.

Eric Crombez Insider Trading History at Abeona Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/2/2026	Sell	16,284	$5.09	$82,885.56	63,456

Eric Crombez Buying and Selling Activity at Abeona Therapeutics

Abeona Therapeutics Company Overview

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Today's Range

Now: $5.95

$5.42

$6.03

50 Day Range

MA: $4.98

$4.23

$5.63

2 Week Range

Now: $5.95

$4.00

$7.54

Volume

1,845,772 shs

Average Volume

1,190,612 shs

Market Capitalization

$338.44 million

P/E Ratio

5.78

Dividend Yield

N/A

Beta

1.35